Page
%P
-
Article
Open AccessMeasurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
-
Article
Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia
-
Article
Open AccessMRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received ...